Clinical trials using a TGFβ inhibitor, increased UVB exposure and/or vitamin D supplementation could potentially represent an important treatment strategy not only for great apes in our care but also be a very valuable and suitable treatment option for humans with increased cardiac, renal, pulmonary, or hepatic fibrosis. This evidence concerns the gene TGFB1 and Hepatic fibrosis.